Prescription Drugs 2 Go

In this study, sorption and desorption of Carbamazepine from water was measured for smectite clays with the surface negative charges compensated with K(+), Ca(2+), NH(4)(+), tetramethylammonium (TMA), trimethylphenylammonium (TMPA) and hexadecyltrimethylammonium (HDTMA) cations. The magnitude of sorption followed the order: TMPA-smectiteHDTMA-smectite>NH(4)-smectite>K-smectite>Ca-smectiteTMA-smectite. The greatest sorption of Carbamazepine by TMPA-smectite is attributed to the interaction of conjugate aromatic moiety in Carbamazepine with the phenyl ring in TMPA through pi-pi interaction. Partitioning process is the primary mechanism for Carbamazepine uptake by HDTMA-smectite. For NH(4)-smectite the urea moiety in Carbamazepine interacts with exchanged cation …

Authors: Hughes JR
The goal of this review is to assess the value of treating versus not treating benign epilepsy (of childhood) with centrotemporal spikes (BECTS). Among 110 recommendations from 96 articles, two-thirds generally favored and one-third generally did not favor treatment with antiepileptic drugs (AEDs). Two studies concluded that all patients should be treated, but most investigators added qualifications, for example, treating those with early onset, multiple seizures at onset, and large numbers of seizures, especially generalized tonic-clonic seizures, and limiting treatment to 1year. Other studies …

Conclusion: CAM use is rather common among PD outpatients, with one in three having experience of CAM practices. Badly-perceived health and higher education were factors significantly associated with CAM utilization. A trend for more female CAM users was also seen. (Source: Parkinsonism and Related Disorders)

Conclusions: Positive response to acute Levodopa test can occur in DLB patients and may be predictive of long-term benefit of chronic Levodopa therapy, although the motor improvement is less impressive than in PD patients. (Source: Parkinsonism and Related Disorders)

Conclusion: Dyskinesia in PD arises as a consequence of the interaction of intrinsic versus extrinsic and modifiable versus non-modifiable factors. Identification and manipulation of modifiable factors for an individual patient may reduce the risk and burden of dyskinesia. Adjustment of Levodopa dose according to body weight during the course of the disease seems to be a significant modifiable risk factor for dyskinesia. (Source: Parkinsonism and Related Disorders)

(Source: Annals of Neurology)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Abstract  Prolonged treatment of Parkinson’s disease (PD) with Levodopa leads to disabling side effects collectively referred to as
‘dyskinesias’. We hypothesized that bioenergetic function in the putamen might play a crucial role in the development of dyskinesias.
To test this hypothesis, we used post mortem samples of the human putamen and applied real time–PCR approaches and gene expression
microarrays. We found that mitochondrial DNA (mtDNA) levels are decreased in patients who have developed dyskinesias, and
mtDNA damage is concomitantly increased. These pathologies were not observed in PD subjects without signs of …

Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ: IPXL), announced that it has completed enrollment of its ADVANCE-PD trial. ADVANCE-PD is a multinational Phase III trial of its late-stage product IPX066 in advanced Parkinson’s disease (PD) patients with motor fluctuations. IPX066 is an investigational extended release <a href="http://www.prescriptiondrugs2go.com/popular-drug-information/c/carbidopa-Levodopa“>Carbidopa-Levodopa product intended to rapidly achieve and sustain effective blood concentrations of Levodopa, potentially improving PD clinical symptom management… (Source: Health News from Medical News Today)

In conclusion, deep brain stimulation of the subthalamic nucleus is a safe procedure with regard to cognitive and behavioural morbidity over long-term follow-up. However, the global benefit partly decreases later in the course of the disease, due to progression of Parkinson’s disease and the appearance of medication- and stimulation-resistant symptoms. (Source: Brain)

Abstract  The aim of this study was to assess the efficacy, safety and tolerability of the antiepileptic compound levetiracetam (LEV)
for the treatment of Levodopa-induced dyskinesia (LID) in Parkinson’s disease (PD). We thus performed a randomized, double-blind,
placebo-controlled, parallel-group pilot study in PD patients with moderate-to-severe LID on stable dopaminergic therapy.
Placebo or LEV was administered twice daily (titrated from 250 to 2,000 mg/day) as add-on therapy. Subjects underwent evaluation
of the unified-PD-rating scale (UPDRS) and the modified abnormal involuntary movement scale (AIMS). The primary outcome variable
was the change of the …